We have studied the effects of ketamine and pentobarbitone on acetylcholine (ACh) release from the rat frontal cortex using microdialysis. Ketamine 25, 50 and 100 mg kg 91 increased ACh release from the frontal cortex to 286%, 253% and 381% of basal release, respectively. In contrast, pentobarbitone 10, 20 and 40 mg kg 91 caused 73%, 78% and 96% inhibition of basal levels, respectively. The results suggest that ketamine and pentobarbitone have opposite effects on ACh release from the rat frontal cortex, as seen previously in the rat hippocampus. (Br.
Cholinergic neurones, which are distributed widely in the brain, have been implicated in a variety of functions, such as memory, learning and motor function. However, the effects of various anaesthetics on cholinergic neurones are not well understood at the molecular level.
Recently, brain microdialysis techniques combined with HPLC-ECD have been well established for measurement of acetylcholine (ACh). In previous studies 1 using this microdialysis technique, we have already shown differential effects of ketamine and pentobarbitone on ACh release from rat hippocampus and striatum, and also demonstrated that the stimulating effect of ketamine might be involved in dopamine D 1 receptor mechanisms.
Determination of ACh release in brain regions such as the cortex, hippocampus, striatum or medial pontine reticular formation is relevant for the study of anaesthetic mechanisms as ACh is thought to be one of the important neurotransmitters involved in the action of anaesthetics. 2 3 The purpose of this study was to investigate the effects of ketamine and pentobarbitone on ACh release from the rat frontal cortex.
Methods and results
Microdialysis experiments were performed on 30 male adult Sprague-Dawley rats, weighing approximately 300 g, during free movement, at least 2 days after implantation of a microdialysis probe. 1 The study was approved by the Animal Welfare Committee of Yokohama City University School of Medicine. The animals, anaesthetized with sodium pentobarbitone 40 mg kg 91 i.p. were placed in a stereotaxic frame (Model SR-6, Narisige Scient Instrument LAB., Japan) and the intracerebral guide cannula (CMA 10, Carnegie Medicine, Sweden) was implanted stereotaxically into the right frontal cortex (coordinates taken from bregma with skull flat: A:3.3 mm, L:2.8 mm, V:0.5 mm from the atlas of Paxinos and Watson) and fixed in place using dental cement. The probes (CMA 11, Carnegie Medicine, Sweden) (2-mm long dialysis membrane, od 0.24 mm, molecular weight cut-off:20 000 Da) were perfused with Ringer's solution containing eserine sulphate 10 mol litre 91 (Wako Pure Chemical Industries Ltd., Japan), an inhibitor of choline esterase, at a rate of 2.0 l min 91 using a microperfusion pump (Model CMA 102, Carnegie Medicine, Sweden). After pre-perfusion with Ringer's solution for 120 min, each sample was collected for 20 min in a cooled polyethylene tube containing 10 l of ethylhomocholine 1 mol litre
91
, an internal standard for high performance liquid chromatography (HPLC) determination. The test drugs were ketamine 25, 50 and 100 mg kg 91 i.p. (Sankyo Ltd., Japan) and pentobarbitone 10, 20 and 40 mg kg 91 i.p. (Abbott Laboratories, USA). After collecting three basal samples, the test drugs were administered i.p. ACh was assayed by a method described previously. 1 The limit of sensitivity was 100 fmol (100 fmo1/50 l injection). At the end of the experiments, the animals were killed with an overdose of diethyl ether, and the position of the probe in the brain was confirmed by visual examination.
Mean ACh recovery through the probes at a rate of 2 l min 91 was 11.1 (SEM 0.7)% (n:5). ACh release was expressed as a percentage of basal values. Basal release was obtained from the mean of three initial collections before administration of the test drugs. The significance of differences between mean values was determined by ANOVA with repeated measures, followed by Scheffé's F test for multiple comparisons. P:0.05 was considered statistically significant.
In this experiment, ketamine 25, 50 and 100 mg kg 91 i.p. and pentobarbitone 10, 20 and 40 mg kg 91 i.p. produced a sleeping state in all rats within 10 min which lasted throughout the experiment. ACh release was stable over 120 min after the beginning of perfusion. Baseline ACh concentration from the frontal cortex in 20-min samples was 0.90 (SEM 0.07) pmol per sample (n:30). Figure 1A shows the effects of ketamine on ACh release from the frontal cortex. Ketamine 25, 50 and 100 mg kg 91 i.p. increased ACh release from the frontal cortex. The maximum increases in ACh release produced by ketamine 25, 50 and 100 mg kg 91 i.p. were 286%, 253% and 381% of basal levels, respectively. The mean increase in ACh release reached a maximum value within 40 min after administration of ketamine 25 and 50 mg kg 91 ; subsequently there was a gradual decrease. However, ACh produced by ketamine 100 mg kg 91 continued to increase over the entire experimental period representing a biphasic pattern.
In contrast, as shown in figure 1B , pentobarbitone 10, 20 and 40 mg kg 91 i.p. decreased ACh release from the frontal cortex. The maximal effects of pentobarbitone 10, 20 and 40 mg kg 91 i.p. were 73%, 78% and 96% inhibition of basal levels, respectively.
Comment
The frontal cortex comprises the motor area and the association area, the so called prefrontal cortex, that is concerned with concentration, attention, initiative and spontaneity. Both the frontal cortex and hippocampus receive cholinergic projections mainly from the anterior and posterior regions of the cholinergic basal nuclear complex, respectively. 4 Behavioural and pharmacological evidence suggests that regulation of cortical and hippocampal cholinergic activity is often similar. The increase in ACh release in the cortex reflects the desynchronized electroencephalogram (EEG) during wakefulness and REM sleep. 5 Pentobarbitone decreased ACh release from the rat frontal cortex, as seen in the rat striatum and hippocampus, 1 which strongly supports the concept that pentobarbitone has a "depressant" anaesthetic effect. It is generally believed that various barbitones such as pentobarbitone produce marked and persistent enhancement of the function of the gamma-aminobutyric acid (GABA) A coupled chloride channel and reduce glutamate-induced depolarization. Furthermore, there is abundant evidence that barbitones depress cortical EEG activity, and cholinergic neural activity in the cortex correlates positively with cortical EEG activity, 3 which is in agreement with our findings.
Ketamine increased ACh release from the rat frontal cortex as seen in the rat hippocampus. 1 However, the increase in ACh produced by ketamine 100 mg kg 91 showed a biphasic pattern, which was not seen in the hippocampus in our previous study. Although reasons for a biphasic pattern are unknown, a high dose of ketamine may affect ACh release from the frontal cortex via mechanisms different from those after a low dose of ketamine.
Ketamine is known to produce psychostimulant defects such as hyperactivity and memory impairment. It is generally accepted that ketamine is a noncompetitive antagonist of NMDA receptors, and there are reports which suggest that ketamine acts at an NMDA recognition site, indicating a role for NMDA receptors in concept learning. NMDA receptors are present in high density in the rat cortex and hippocampus. 6 Hasegawa and colleagues showed that MK-801, another non-competitive antagonist at the NMDA receptor but not an anaesthetic agent, increases ACh release in the rat parietal cortex and that the facilitatory effects of MK-801 on cortical ACh release are blocked by NMDA. 7 This may indicate that the facilitatory effect of ketamine on ACh release from the rat cortex appears to be involved in the antagonism of NMDA receptors, as shown with our previous data for rat hippocampal ACh release. 1 Our results demonstrated that both ketamine and pentobarbitone produced loss of consciousness, but opposite effects on ACh release from the cortex. This suggests that ACh release in the frontal cortex is concerned with psychomimetic effects other than consciousness. These opposing effects of ketamine and pentobarbitone on cortical ACh release lead us to speculate that the unfavourable psychomimetic actions of ketamine such as bad dreams may be suppressed by simultaneously administered barbitones. Furthermore, several classes of NMDA antagonists, including ketamine, are known to produce morphological damage in neurones in the cerebral cortex and this may be prevented by barbitones, benzodiazepines, or both.
